Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study

Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

(2017) Gabriel N. Hortobagyi et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer

(2013) Eva Ciruelos et al.   ANTI-CANCER DRUGS

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

(2013) Diana E. Ramirez-Ardila et al.   BREAST CANCER RESEARCH AND TREATMENT

Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial

(2013) J M S Bartlett et al.   BRITISH JOURNAL OF CANCER

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

(2013) Kamal S. Saini et al.   CANCER TREATMENT REVIEWS

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

(2013) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

The Role of Genetic Markers in the Management of Prostate Cancer

(2012) Atish D. Choudhury et al.   EUROPEAN UROLOGY

Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression

(2012) Melanie Spears et al.   JOURNAL OF PATHOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110  (PIK3CA)

(2012) J. E. Burke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

(2011) Leiping Wang et al.   BMC CANCER

Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial

(2011) John M.S. Bartlett et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

(2011) Cornelis JH van de Velde et al.   LANCET

Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer

(2011) Sampoorna Satheesha et al.   Molecular Cancer

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

(2011) Filip Janku et al.   PLoS One

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer

(2010) Vicky S. Sabine et al.   BREAST CANCER RESEARCH AND TREATMENT

Biomarkers and Patient Selection for PI3K/Akt/mTOR Targeted Therapies: Current Status and Future Directions

(2010) John M.S. Bartlett   Clinical Breast Cancer

Bladder cancer: translating molecular genetic insights into clinical practice

(2010) Liang Cheng et al.   HUMAN PATHOLOGY

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

(2010) S. Loi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

(2009) K. Kalinsky et al.   CLINICAL CANCER RESEARCH

Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic

(2009) Nadine Dannemann et al.   INTERNATIONAL JOURNAL OF CANCER

PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients

(2008) Yuen-Liang Lai et al.   ANNALS OF SURGICAL ONCOLOGY

Multiplexed Assays for Detection of Mutations in PIK3CA

(2008) R. E. Board et al.   CLINICAL CHEMISTRY

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE